Integration of cytogenetic aberrations and in silico pathway enrichment identifies novel candidate genes in esophageal squamous cell carcinoma

Table 2 Stage wise comparison of chromosomal aberrations in males and female patients and in controls, mean ± SD

Chromosomal aberration	Controls		Patients with esophageal cancer
			Stage I		Stage II		Stage III		Stage IV
	Males (n = 59)	Females (n = 76)	Males (n = 4)	Females (n = 4)	Males (n = 19)	Females (n = 22)	Males (n = 30)	Females (n = 21)	Males (n = 6)	Females (n = 3)
Mean (%) aberrant metaphases	10.53 ± 3.0	12.3 ± 4.7	19.15 ± 4.62	17.25 ± 4.90	25.52 ± 4.9	23.52 ± 8.4	27.06 ± 8.73	27.46 ± 9.00	33.7 ± 4.86	34.3 ± 3.8
P value	0.01a		0.59		0.36		0.87		0.75
Mean (%) metaphases with structural aberrations	4.6 ± 2.9	4.8 ± 2.5	12.07 ± 3.41	7.0 ± 3.60	7.35 ± 4.28	6.01 ± 6.24	8.17 ± 5.10	13.04 ± 13.81	10.18 ± 4.39	17.66 ± 3.29
P value	0.66		0.08		0.43		0.08		0.23
Mean (%) metaphases with numerical aberrations	4.9 ± 2.0	6.5 ± 3.8	9.07 ± 3.55	8.0 ± 2.73	15.82 ± 4.49	15.54 ± 5.86	15.55 ± 8.54	15.75 ± 8.79	16.35 ± 4.46	14.43 ± 0.80
P value	0.004b		0.64		0.89		0.93		0.49
Mean (%) metaphases with both structural and numerical aberrations	2.2 ± 1.1	2.4 ± 0.9	1.0 ± 0.0	3.0 ± 1.41	2.66 ± 1.34	2.33 ± 1.31	3.23 ± 1.62	3.45 ± 4.83	4.83 ± 3.34	2.6 ± 205
P value	0.24		-		0.43		0.81		0.33

^aP < 0.05.

^bP < 0.01.